ChemoCentryx Identifies Novel Orally Administered Immune Checkpoint Inhibitor CCX559 for Next Generation Cancer Treatment
24 juin 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., June 24, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced that it has identified an orally administered checkpoint inhibitor, CCX559, and plans to...
ChemoCentryx Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
15 juin 2020 16h05 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., June 15, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq: CCXI) announced today the completion of its follow-on offering of 5,200,000 shares of its common...
ChemoCentryx Prices Public Offering of Common Stock
10 juin 2020 21h32 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has priced an underwritten public offering of 5,200,000 shares of its common stock...
ChemoCentryx Announces Proposed Public Offering of Common Stock
10 juin 2020 16h08 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., June 10, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has commenced an underwritten public offering of its common stock. In connection...
ChemoCentryx Phase III ADVOCATE Trial of Avacopan in ANCA-Associated Vasculitis Highlighted in Oral Plenary Presentations at EULAR and ERA-EDTA Congresses
03 juin 2020 07h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., June 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) today announced presentations highlighting outcomes of the Company’s Phase III ADVOCATE trial as part of...
ChemoCentryx and VFMCRP Announce Topline Data from Phase II LUMINA-1 Trial of CCX140 in Focal Segmental Glomerulosclerosis (FSGS)
18 mai 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif. and ST GALLEN, CH, May 18, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (NASDAQ: CCXI) and Vifor Fresenius Medical Care Renal Pharma (VFMCRP) today announced topline data from...
ChemoCentryx Reports First Quarter 2020 Financial Results and Recent Highlights
11 mai 2020 16h05 HE
|
ChemoCentryx, Inc.
-- On track to file U.S. New Drug Application (NDA) for avacopan in ANCA-associated vasculitis mid-year -- -- Topline data from CCX140 LUMINA-1 Phase II clinical trial in Focal Segmental...
ChemoCentryx to Hold First Quarter 2020 Financial Results Conference Call on Monday, May 11, 2020
04 mai 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., May 04, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's first quarter 2020 financial results will be released after market...
ChemoCentryx Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Highlights
10 mars 2020 16h05 HE
|
ChemoCentryx, Inc.
-- Announced positive topline data from pivotal Phase III ADVOCATE trial for ANCA-vasculitis in Q4; U.S. NDA filing expected mid-2020 -- -- “2020 4-Sight” on the horizon with topline data from four...
ChemoCentryx to Hold Fourth Quarter and Full Year 2019 Financial Results Conference Call on Tuesday, March 10, 2020
03 mars 2020 08h30 HE
|
ChemoCentryx, Inc.
MOUNTAIN VIEW, Calif., March 03, 2020 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's fourth quarter and full year 2019 financial results will be released...